CLCS
Price:
$0.57248
Market Cap:
$24.88M
Cell Source, Inc., a biotechnology company, develops cell therapy treatments based on the management of immune tolerance. The company's lead product is the Veto Cell immune system management technology, which is an immune tolerance biotechnology that enables the selective blocking of immune responses. Its Veto Cell technology is used in various applications, including treatment of lymphoma, leukemia, and multiple myeloma through facilitation of the stem cell transplantation acceptance, as well as treatment of end stage kidney disease and other non-malignant organ diseases, and various cancers and non-malignant diseases. Cell Source, Inc. was founded in 2012 and is headquartered in New York, ...[Read more]
Industry
Biotechnology
IPO Date
2014-05-01
Stock Exchange
PNK
Ticker
CLCS
According to Cell Source, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 34.64M. This represents a change of 68.15% compared to the average of 20.60M of the last 4 quarters.
The mean historical Enterprise Value of Cell Source, Inc. over the last ten years is 30.25M. The current 34.64M Enterprise Value has changed 11.35% with respect to the historical average. Over the past ten years (40 quarters), CLCS's Enterprise Value was at its highest in in the June 2021 quarter at 70.49M. The Enterprise Value was at its lowest in in the September 2022 quarter at 7.20M.
Average
30.25M
Median
28.66M
Minimum
8.64M
Maximum
62.76M
Discovering the peaks and valleys of Cell Source, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 203.36%
Maximum Annual Enterprise Value = 62.76M
Minimum Annual Increase = -60.09%
Minimum Annual Enterprise Value = 8.64M
Year | Enterprise Value | Change |
---|---|---|
2023 | 23.59M | -36.74% |
2022 | 37.29M | -23.53% |
2021 | 48.77M | -22.30% |
2020 | 62.76M | 86.05% |
2019 | 33.73M | 45.01% |
2018 | 23.26M | 169.11% |
2017 | 8.64M | -41.88% |
2016 | 14.87M | -60.09% |
2015 | 37.27M | 203.36% |
2014 | 12.28M | 6.78% |
The current Enterprise Value of Cell Source, Inc. (CLCS) is less than than its 3-year, less than than its 5-year, and greater than its 10-year historical averages
3-year avg
36.55M
5-year avg
41.23M
10-year avg
30.25M
Cell Source, Inc.’s Enterprise Value is greater than Emmaus Life Sciences, Inc. (33.54M), greater than Adhera Therapeutics, Inc. (10.81M), greater than PolarityTE, Inc. (-6308329.00), less than ZIVO Bioscience, Inc. (73.95M), greater than Pasithea Therapeutics Corp. (-5435245.00), less than Nutriband Inc. (46.88M), greater than MediciNova, Inc. (-41974173594.00), less than Eliem Therapeutics, Inc. (119.64M), greater than Panbela Therapeutics, Inc. (4.75M), greater than Virpax Pharmaceuticals, Inc. (4.57M), greater than Revelation Biosciences, Inc. (-3300245.00), greater than Biodexa Pharmaceuticals Plc (-2820215.62), less than Praxis Precision Medicines, Inc. (1.22B), greater than Cardio Diagnostics Holdings, Inc. (9.47M), less than Sigilon Therapeutics, Inc. (42.21M), greater than Sonnet BioTherapeutics Holdings, Inc. (-907921.00), greater than ZyVersa Therapeutics, Inc. (2.53M), less than X4 Pharmaceuticals, Inc. (38.44M), greater than eFFECTOR Therapeutics, Inc. (4.74M), less than Landos Biopharma, Inc. (42.62M), greater than Apexigen, Inc. (-5121682.00), greater than Navidea Biopharmaceuticals, Inc. (-2504975.00), greater than Angion Biomedica Corp. (22.43M),
Company | Enterprise Value | Market cap |
---|---|---|
33.54M | $1.73M | |
10.81M | $17.33K | |
-6308329.00 | $1.78M | |
73.95M | $74.08M | |
-5435245.00 | $3.93M | |
46.88M | $82.96M | |
-41974173594.00 | $104.47M | |
119.64M | $342.68M | |
4.75M | $1.69M | |
4.57M | $4.59M | |
-3300245.00 | $3.24M | |
-2820215.62 | $2.32M | |
1.22B | $1.39B | |
9.47M | $10.73M | |
42.21M | $56.22M | |
-907921.00 | $2.50M | |
2.53M | $2.65M | |
38.44M | $57.64M | |
4.74M | $941.00 | |
42.62M | $71.68M | |
-5121682.00 | $9.57M | |
-2504975.00 | $100.08K | |
22.43M | $30.11M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Cell Source, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Cell Source, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Cell Source, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Cell Source, Inc. (CLCS)?
What is the 3-year average Enterprise Value for Cell Source, Inc. (CLCS)?
What is the 5-year average Enterprise Value for Cell Source, Inc. (CLCS)?
How does the current Enterprise Value for Cell Source, Inc. (CLCS) compare to its historical average?